TY  - JOUR
PY  - 2019//
TI  - Spotlight on brodalumab in the treatment of plaque psoriasis: The evidence to date
JO  - Clinical, cosmetic and investigational dermatology
A1  - Galluzzo, M.
A1  - D'Adamio, S.
A1  - Massaro, A.
A1  - Piccolo, A.
A1  - Bianchi, L.
A1  - Talamonti, M.
SP  - 311
EP  - 321
VL  - 12
IS  - 
N2  - The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab). © 2019 Galluzzo et al.<p /> <p>Language: en</p>
LA  - en
SN  - 1178-7015
UR  - http://dx.doi.org/10.2147/CCID.S165605
ID  - ref1
ER  -